Venetoclax and Ibrutinib in Treating in Participants With Chronic Lymphocytic Leukemia and Ibrutinib Resistance Mutations
Clinical trial NCT03513562 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT03513562
- Sponsor
- Ohio State University Comprehensive Cancer Center
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2019-03-26
- Primary completion
- 2026-12-31
- Enrollment
- 28
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.